Hiv Clinical Trial
Official title:
Interrupting HIV and TB Stigma in the Household During TB Contact Investigation in Uganda
Verified date | February 2024 |
Source | Yale University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The investigators will carry out a prospective, household cluster-randomized, implementation trial evaluating a complex, multi-component, social and behavioral intervention designed to normalize the acceptance of HIV testing in the household and increase diagnosis of HIV.
Status | Completed |
Enrollment | 612 |
Est. completion date | August 30, 2022 |
Est. primary completion date | July 29, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 15 Years and older |
Eligibility | Index Patient and Household Eligibility: - Index patient is eligible for contact investigation (TB patient of any age identified in the facility's National TB and Leprosy Programme (NTLP) TB Treatment Register as initiating treatment or returning for 2-week follow-up) - Index patient or legal guardian agrees to study procedures in addition to routine contact investigation - Index patient has at least 2 self-reported household contacts age 15 or above - Household is within the boundaries of the Kampala Capital City Authority, Uganda - Does not have multi-drug resistant (MDR) TB Contact Participant Eligibility: - Household contact age =15 years - Agrees to study procedures in addition to routine contact investigation |
Country | Name | City | State |
---|---|---|---|
Uganda | Makerere University | Kampala |
Lead Sponsor | Collaborator |
---|---|
Yale University | Fogarty International Center of the National Institute of Health, Makerere University, National Institute of Mental Health (NIMH), New York University, Walimu |
Uganda,
Armstrong-Hough M, Ggita J, Gupta AJ, Shelby T, Nangendo J, Ayen DO, Davis JL, Katamba A. Assessing a norming intervention to promote acceptance of HIV testing and reduce stigma during household tuberculosis contact investigation: protocol for a cluster-randomised trial. BMJ Open. 2022 May 25;12(5):e061508. doi: 10.1136/bmjopen-2022-061508. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Count of Social Influence Nominations (Participants) by the Index Patient That Align With Nominations by the Household Contacts | The investigators will assess the concordance of index patients' perceptions of their household contacts' influence on health decisions within the household with the perceptions of the rest of their household. To do so, the investigators will measure the number of participants that provide social influence nominations that align with nominations by the household contacts in the intervention arm. | up to 8 weeks | |
Primary | Proportion of Contacts Accepting HIV Testing | To test the hypothesis that a norming intervention can increase test uptake, the investigators will compare testing uptake among the intervention households and control households using cluster-adjusted chi-squared tests of proportion and by fitting mixed effects logistic regression models with two levels (household, contact). The effect of the intervention will then be evaluated by comparing adjusted slope differences in the primary outcomes (test uptake) between the intervention and the control arms, using random intercept mixed logit models to account for clustering by household. | up to 8 weeks | |
Secondary | Change in Score of Perceived HIV Stigma | Change in HIV Stigma will be evaluated by measuring the change in HIV-TB stigma as measured by the Van Rie paired HIV-TB Stigma Scales (adapted for use in Uganda) using multilevel models. The investigators will use mixed effects Poisson regression models to evaluate changes in HIV stigma measured after the household visit among a two-stage,stratified random sample of participants.
Van Rie Perceived TB and HIV Stigma scales adapted and validated in the Ugandan context are used. Scores range from 0 to 100 (standardized scale). Higher values represent higher levels of perceived stigma. The timeframe has been updated to reflect changes in follow up due to COVID-19 restrictions. |
Baseline to End of Interview (Up to 8 hours) | |
Secondary | Change in Score of Perceived TB Stigma | Change in TB Stigma will be evaluated by measuring the change in perceived TB stigma as measured by the Van Rie paired HIV-TB Stigma Scales (adapted for use in Uganda) using multilevel models. The investigators will use mixed effects Poisson regression models to evaluate changes in TB stigma measured after the household visit among a two-stage,stratified random sample of participants.
Van Rie Perceived TB and HIV Stigma scales adapted and validated in the Ugandan context are used. Scores range from 0 to 100 (standardized scale). Higher values represent higher levels of perceived stigma. The timeframe has been updated to reflect changes in follow up due to COVID-19 restrictions. |
Baseline to End of Interview (Up to 8 hours) | |
Secondary | Change in Effects of Perceived HIV Stigma on HIV Test Uptake | The investigators will conduct a causal mediation analysis to determine the degree to which the effects of the intervention on HIV stigma explain the improvement in HIV test uptake using observed-variable structural equation modeling. HIV stigma will be measured using the Van Rie paired HIV-TB Stigma Scales (adapted for use in Uganda) and standardized scores (0 to 100) will be utilized. Higher score represents higher levels of perceived stigma. | Baseline to Immediately post intervention (up to 8 hours) | |
Secondary | Change in Effects of Perceived TB Stigma on HIV Test Uptake | The investigators will conduct a causal mediation analysis to determine the degree to which the effects of the intervention on TB stigma explain the improvement in HIV test uptake using observed-variable structural equation modeling. TB stigma will be measured using the Van Rie paired HIV-TB Stigma Scales (adapted for use in Uganda) and standardized scores (0 to 100) will be utilized. Higher score represents higher levels of perceived stigma. | Baseline to End of Interview (Up to 8 hours) | |
Secondary | Proportion of Index Patient Nominated Household Members Who Accept HIV Test | The investigators will measure the proportion of testing preference predictions made by the index patient about their household contacts that were accurate, that is, the proportion of household members who accepted the HIV test among those nominated by the index patient as being most likely to accept the HIV test. The proportion of first testers who accepted the HIV test in the intervention arm will be compared to the proportion of first testers who took the HIV test in the control arm. | up to 8 weeks | |
Secondary | Number of Social Support Household Contacts Deciding to Test for HIV | The investigators will estimate in the intervention arm the effect of first testers' decision to disclose on subsequent testers' decisions to test in the intervention arm using a logistic regression model. This will be assessed with relative risk of first testers' decision to disclose testing decision on subsequent household members decision to test for HIV. | up to 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06162897 -
Case Management Dyad
|
N/A | |
Completed |
NCT03999411 -
Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients
|
Phase 4 | |
Completed |
NCT02528773 -
Efficacy of ART to Interrupt HIV Transmission Networks
|
||
Active, not recruiting |
NCT05454839 -
Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in South Africa
|
||
Recruiting |
NCT05322629 -
Stepped Care to Optimize PrEP Effectiveness in Pregnant and Postpartum Women
|
N/A | |
Completed |
NCT02579135 -
Reducing HIV Risk Among Adolescents: Evaluating Project HEART
|
N/A | |
Active, not recruiting |
NCT01790373 -
Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence
|
N/A | |
Not yet recruiting |
NCT06044792 -
The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
|
||
Completed |
NCT04039217 -
Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM
|
Phase 4 | |
Active, not recruiting |
NCT04519970 -
Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK)
|
N/A | |
Completed |
NCT04124536 -
Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women
|
N/A | |
Recruiting |
NCT05599581 -
Tu'Washindi RCT: Adolescent Girls in Kenya Taking Control of Their Health
|
N/A | |
Active, not recruiting |
NCT04588883 -
Strengthening Families Living With HIV in Kenya
|
N/A | |
Completed |
NCT02758093 -
Speed of Processing Training in Adults With HIV
|
N/A | |
Completed |
NCT02500446 -
Dolutegravir Impact on Residual Replication
|
Phase 4 | |
Completed |
NCT03805451 -
Life Steps for PrEP for Youth
|
N/A | |
Active, not recruiting |
NCT03902431 -
Translating the ABCS Into HIV Care
|
N/A | |
Completed |
NCT00729391 -
Women-Focused HIV Prevention in the Western Cape
|
Phase 2/Phase 3 | |
Recruiting |
NCT05736588 -
Elimisha HPV (Human Papillomavirus)
|
N/A | |
Recruiting |
NCT03589040 -
Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant
|
Phase 2 |